Copper Oxodotreotide Cu-64

Copper Oxodotreotide Cu-64 Uses, Dosage, Side Effects, Food Interaction and all others data.

Copper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over 68 Ga-labeled somatostatin analogs for positron emission tomography (PET). Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution. Further studies should be performed to compare the two tracers.

Further, PET using Copper Cu 64 dotatate has been found to perform better than the current gold standard of single-photon emission computed tomography (SPECT) using 111In-DTPA-octreotide. In a head-to-head trial, the former tracer detected twice as many lesions as the latter.

Table Of contents

• Copper Oxodotreotide Cu-64
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Copper Oxodotreotide Cu-64
Generic	Copper oxodotreotide Cu-64
Copper oxodotreotide Cu-64 Other Names	64Cu-dotatate, Copper 64-DOTA-tate, Copper Cu-64 dotatate, Copper dotatate Cu-64, Copper oxodotreotide Cu-64
Type
Formula	C65H88CuN14O19S2
Weight	Average: 1497.55 Monoisotopic: 1496.508926883
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Copper Oxodotreotide Cu-64 is a Cu labeled somatostatin analog used in positron emission tomography to detect certain types of neuroendocrine tumors.

Copper Cu 64 Dotatate is a radiopharmaceutical used with positron emission tomography(PET) to locate somatostatin receptor-positive neuroendocrine tumors.

Copper Oxodotreotide Cu-64 is also used to associated treatment for these conditions: Somatostatin Receptor Positive Neuroendocrine Tumours

How Copper Oxodotreotide Cu-64 works

The main target of the positron-emitting Copper Cu 64 dotatate is somatostatin receptor type 2 (SSTR2). SSTR2 is frequently overexpressed in malignant neuroendocrine cells; therefore, accumulation of the radionuclide at the site permits PET imaging to occur.

Toxicity

If radiation overdose occurs, patients should be advised to drink plenty of water and to void frequently to increase the rate of elimination of the radionuclide. In certain cases, it may be appropriate to administer a diuretic.

Food Interaction

• Take with fluids. Patients should remain well hydrated before and after imaging with copper Cu 64 dotatate to limit radiation exposure.

Elimination Route

Radioactivity can be identified in the kidney, liver, adrenal glands, spleen, and pituitary glands 1-3 hours after copper Cu 64 dotatate is administered.

Half Life

The half-life of Copper Cu 64 is 12.7 hours.

Elimination Route

16% - 40% of the original radioactivity was detected in urine 6 hours after the intravenous administration of a single dose.

Innovators Monograph

You find simplified version here Copper Oxodotreotide Cu-64